Previous 10 | Next 10 |
home / stock / ptct / ptct articles
Thursday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion following...
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether PTC Therapeutics, Inc. (...
In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a delay to the planned submission of sepiapterin in ph...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 100 points on Thursday. The Dow traded down 0.43% to 3...
Gainers SeaStar Medical Holding Corporation (NASDAQ: ICU) shares climbed 36.4% to $1.0516. SeaStar medical shares jumped 70% on Wednesday after t...
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 30 points on Thursday. Here are some big stocks recording gains in tod...
Raymond James increased the price target for Vital Energy, Inc. (NYSE: VTLE) from $54 to $67. Raymond James analyst John Freeman maintained an O...
It’s a quiet start to the week for the U.S. stock market, with investors eagerly anticipating the crucial Federal Reserve interest rate decis...
Piper Sandler cut the price target for IBEX Limited (NASDAQ: IBEX) from $24 to $17. Piper Sandler analyst Arvind Ramnani maintained an Overweigh...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....
CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review PR Newswire - PTC to submit a request for re-examination - WARREN, N.J. , June 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announce...
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients PR Newswire - FDA lifts PTC518 partial clinical hold based on PIVOT-HD data - - Conference call and webcast to be held ...